As members of the greater Baltimore, Maryland and greater Irvine, California communities, we take great pride and honor to be named a recipient of the 2013 Bridging the Gap Award - Brian Meshkin, CEO, Proove Biosciences
Irvine, CA (PRWEB) November 26, 2013
Proove Biosciences, the leading personalized pain medicine laboratory, and CEO, Brian Meshkin, were one of 13 winners of the 2013 Bridging the Gap Awards, an award given to minority-owned and women-owned firms for achievement for their efforts to strengthen business development.
The Greater Baltimore Committee recognized Brian Meshkin and Proove as a leading minority-owned business. The GBC is an organization that aims to improve the business climate of the Greater Baltimore region by organizing corporate and civic leadership to develop strategies that solve problems with the region’s competitiveness and viability.
As stated by the GBC, “Brian Meshkin, son of an immigrant [born in Iran] from Pakistan who, along with his wife Catherine, founded Proove Biosciences, Inc. in the midst of the Great Recession. They developed, among other things, a one-of-a-kind genetic test to identify patients pre-disposed to the risk of pain medication misuse. After a few years dedicated to research and development, the Meshkins put their business model into action and built their Howard County-based firm into a commercial market leader advancing the concept of personalized medicine in pain management.”
Proove Biosciences President and Founder, Brian Meshkin states, “As members of the greater Baltimore, Maryland and greater Irvine, California communities, we take great pride and honor to be named a recipient of the 2013 Bridging the Gap Award from the GBC. Proove Biosciences was founded with a vision and a mission to change the world. We are proud to demonstrate how to bridge the achievement gap.”
About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).